產品詳情
簡單介紹：
Anti-SPRN抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-SPRN抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-SPRN
Cat. Number:
Anti-SPRN抗體KL-4566R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are manifested as genetic, infectious or sporadic lethal neurodegenerative disorders involving alterations of the prion protein (PrP). Constitutively expressed in normal ***** brain, cellular PrP (PrP(C)) is sensitive to proteinase K digestion and is converted Anti-SPRN抗體to the disease form, PrPSc, through alterations in protein folding conformation, which make it resistant proteases. SPRN (shadow of prion protein), also known as SHO or SHADOO, is a 151 amino acid cytoplasmic protein that is mainly expressed in brain. SPRN is considered a prion-like protein that has PrP(C)-like neuroprotective activity and may act as a modulator for the biological actions of normal and abnormal PrP. In humans, mutations in the gene encoding SPRN may be associated with variant and sporadic Creutzfeldt-Jakob disease, a degenerative neurological disorder that is incurable and invariably fatal.
Also known as:
rCG47959; shadow of prion protein; Anti-SPRN抗體SHO; Protein shadoo; bA108K14.1; C630041J07; FLJ41197; SPRN; Shadow of prion protein precursor; SPRN_MOUSE.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Mouse, Rat, .
●
Immunogen: KLH conjugated syntheticAnti-SPRN抗體 peptide derived from mouse Shadow(CT).
●
Predicted Molecular Weight: 12kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-SPRN抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-SPRN抗體
Optimal working dilutions must be determined by the end user.
